Ixekizumab for treating ankylosing spondylitis

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Axial spondyloarthritis (axSpA) encompasses ankylosing spondylitis and nonradiographic axSpA.
• The IL-17 pathway is implicated in axSpA pathogenesis.
• Limited targeted treatment options exist for axSpA.

Purpose of the Study:

• To review the pharmacologic properties of Ixekizumab (IXE).
• To evaluate the efficacy and safety of IXE in radiographic axSpA.
• To assess IXE's impact on quality of life outcomes.

Main Methods:

• Review of Ixekizumab's pharmacology.
• Evaluation of clinical trial data for IXE in radiographic axSpA.
• Assessment of patient-reported outcomes and safety profiles.

Main Results:

• Ixekizumab (IXE) is an IL-17A inhibitor with supporting data for radiographic axSpA.
• IXE demonstrates improved clinical efficacy, patient-reported outcomes, and imaging outcomes.
• IXE shows an acceptable safety profile in patients with radiographic axSpA.

Conclusions:

• Ixekizumab is a viable treatment option for radiographic axSpA.
• IXE can be used in both tumor necrosis factor inhibitor (TNFi)-naive patients and those with inadequate response or intolerance to TNFi.
• The IL-17 pathway inhibition with IXE offers a new therapeutic avenue for axSpA management.